Safety of statins - Focus on clinical pharmacokinetics and drug interactions

被引:485
作者
Bellosta, S [1 ]
Paoletti, R [1 ]
Corsini, A [1 ]
机构
[1] Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy
关键词
drug interactions; fibrates; rhabdomyolysis; safety; statins;
D O I
10.1161/01.CIR.0000131519.15067.1f
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Statin monotherapy is generally well tolerated, with a low frequency of adverse events. The most important adverse effects associated with statins are myopathy and an asymptomatic increase in hepatic transaminases, both of which occur infrequently. Because statins are prescribed on a long-term basis, however, possible interactions with other drugs deserve particular attention, as many patients will typically receive pharmacological therapy for concomitant conditions during the course of statin treatment. This review summarizes the pharmacokinetic properties of statins and emphasizes their clinically relevant drug interactions.
引用
收藏
页码:50 / 57
页数:8
相关论文
共 65 条
[1]   Beneficial effects of Pravastatin (±colestyramine/niacin) initiated immediately after a coronary event (the randomized lipid-coronary artery disease [L-CAD] study) [J].
Arntz, HR ;
Agrawal, R ;
Wunderlich, W ;
Schnitzer, L ;
Stern, R ;
Fischer, F ;
Schultheiss, HP .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (12) :1293-1298
[2]   Role of transport proteins in drug absorption, distribution and excretion [J].
Ayrton, A ;
Morgan, P .
XENOBIOTICA, 2001, 31 (8-9) :469-497
[3]   The interaction of diltiazem with lovastatin and pravastatin [J].
Azie, NE ;
Brater, DC ;
Becker, PA ;
Jones, DR ;
Hall, SD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (04) :369-377
[4]   Risk for myopathy with statin therapy in high-risk patients [J].
Ballantyne, CM ;
Corsini, A ;
Davidson, MH ;
Holdaas, H ;
Jacobson, TA ;
Leitersdorf, E ;
März, W ;
Reckless, JPD ;
Stein, EA .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (05) :553-564
[5]  
BIZZARO N, 1992, CLIN CHEM, V38, P1504
[6]   'Fire and forget?' - pharmacological considerations in coronary care [J].
Bottorff, M .
ATHEROSCLEROSIS, 1999, 147 :S23-S30
[7]   Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion [J].
Boyd, RA ;
Stern, RH ;
Stewart, BH ;
Wu, XC ;
Reyner, EL ;
Zegarac, EA ;
Randinitis, EJ ;
Whitfield, L .
JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (01) :91-98
[8]   Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease [J].
Brown, BG ;
Zhao, XQ ;
Chait, A ;
Fisher, LD ;
Cheung, MC ;
Morse, JS ;
Dowdy, AA ;
Marino, EK ;
Bolson, EL ;
Alaupovic, P ;
Frohlich, J ;
Albers, JJ ;
Serafini, L ;
Huss-Frechette, E ;
Wang, S ;
DeAngelis, D ;
Dodek, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (22) :1583-1592
[9]   Rhabdomyolysis due to probable interaction between simvastatin and ritonavir [J].
Cheng, CH ;
Miller, C ;
Lowe, C ;
Pearson, VE .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (08) :728-730
[10]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3